Tags

Type your tag names separated by a space and hit enter

Obesity and outcomes in premenopausal and postmenopausal breast cancer.
Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1686-91.CE

Abstract

PURPOSE

Obesity is associated with adverse outcomes in postmenopausal women with breast cancer. In premenopausal women, the association is less clear.

METHODS

A population-based sample of 1,360 Australian women with breast cancer before the age of 60 years, 47% diagnosed before age 40, and 74% premenopausal, was studied prospectively for a median of 5 years (range, 0.2-10.8 years). Obesity was defined as a body mass index of > or =30 kg/m2. The hazard ratio (HR) for adverse clinical outcome associated with obesity was estimated using Cox proportional hazard survival models.

RESULTS

Obesity increased with age (P < 0.001) and was associated with increased breast cancer recurrence (P = 0.02) and death (P = 0.06), larger tumors (P = 0.002), and more involved axillary nodes (P = 0.003) but not with hormone receptor status (P > or = 0.6) or with first cycle adjuvant chemotherapy dose reductions (P = 0.1). Adjusting for number of axillary nodes, age at diagnosis, tumor size, grade, and hormone receptor status, obese women of all ages were more likely than nonobese women to have disease recurrence [HR, 1.57; 95% confidence interval (95% CI), 1.11-2.22; P = 0.02] and to die from any cause during follow-up (HR, 1.56; 95% CI, 1.01-2.40; P = 0.05). In premenopausal women, the adjusted HRs were 1.50 (95% CI, 1.00-2.26; P = 0.06) and 1.71 (95% CI, 1.05-2.77; P = 0.04), respectively.

CONCLUSIONS

Obesity is independently associated with poorer outcomes in premenopausal women, as it is in postmenopausal women, and this is not entirely explained by differences in tumor size or nodal status. Given the high and increasing prevalence of obesity in western countries, more research on improving the treatment of obese breast cancer patients is warranted.

Authors+Show Affiliations

Peter MacCallum Cancer Centre, 723 Swanston Street, Carlton, Victoria 3053, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

16030102

Citation

Loi, Sherene, et al. "Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 14, no. 7, 2005, pp. 1686-91.
Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1686-91.
Loi, S., Milne, R. L., Friedlander, M. L., McCredie, M. R., Giles, G. G., Hopper, J. L., & Phillips, K. A. (2005). Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 14(7), 1686-91.
Loi S, et al. Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1686-91. PubMed PMID: 16030102.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Obesity and outcomes in premenopausal and postmenopausal breast cancer. AU - Loi,Sherene, AU - Milne,Roger L, AU - Friedlander,Michael L, AU - McCredie,Margaret R E, AU - Giles,Graham G, AU - Hopper,John L, AU - Phillips,Kelly-Anne, PY - 2005/7/21/pubmed PY - 2005/10/13/medline PY - 2005/7/21/entrez SP - 1686 EP - 91 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol Biomarkers Prev VL - 14 IS - 7 N2 - PURPOSE: Obesity is associated with adverse outcomes in postmenopausal women with breast cancer. In premenopausal women, the association is less clear. METHODS: A population-based sample of 1,360 Australian women with breast cancer before the age of 60 years, 47% diagnosed before age 40, and 74% premenopausal, was studied prospectively for a median of 5 years (range, 0.2-10.8 years). Obesity was defined as a body mass index of > or =30 kg/m2. The hazard ratio (HR) for adverse clinical outcome associated with obesity was estimated using Cox proportional hazard survival models. RESULTS: Obesity increased with age (P < 0.001) and was associated with increased breast cancer recurrence (P = 0.02) and death (P = 0.06), larger tumors (P = 0.002), and more involved axillary nodes (P = 0.003) but not with hormone receptor status (P > or = 0.6) or with first cycle adjuvant chemotherapy dose reductions (P = 0.1). Adjusting for number of axillary nodes, age at diagnosis, tumor size, grade, and hormone receptor status, obese women of all ages were more likely than nonobese women to have disease recurrence [HR, 1.57; 95% confidence interval (95% CI), 1.11-2.22; P = 0.02] and to die from any cause during follow-up (HR, 1.56; 95% CI, 1.01-2.40; P = 0.05). In premenopausal women, the adjusted HRs were 1.50 (95% CI, 1.00-2.26; P = 0.06) and 1.71 (95% CI, 1.05-2.77; P = 0.04), respectively. CONCLUSIONS: Obesity is independently associated with poorer outcomes in premenopausal women, as it is in postmenopausal women, and this is not entirely explained by differences in tumor size or nodal status. Given the high and increasing prevalence of obesity in western countries, more research on improving the treatment of obese breast cancer patients is warranted. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/16030102/full_citation DB - PRIME DP - Unbound Medicine ER -